Nutra Pharma CEO Rik Deitsch resigns amid SEC settlement; Dr. Michael Flax appointed CEO/CFO/Chairman

NUTRA PHARMA CORP

Rik Deitsch resigned as CEO, Director, Chairman, and CFO effective March 19, 2024, due to SEC settlement.
SEC settlement permanently enjoins company, Deitsch, and McManus from securities law violations; 3-year officer/director and penny stock bars for Deitsch.
Disgorgement and civil penalties for all defendants, and a possible penny stock bar for McManus, left for later court resolution.
Dr. Michael Flax appointed CEO, CFO, and Chairman effective March 20, 2024; previously served as CEO of Nutra Pharma from 2001-2002.
Rik Deitsch remains as Operations Manager, reporting to VP of Operations Joe Lucas.

item 5.02 item 8.01 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Rik J. Deitsch

Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer

NUTRA PHARMA CORP

Effective: 2024-03-19
Successor: Michael Flax
Filed: March 22, 2024, 7:59 PM ET

On March 19, 2024, Mr. Deitsch submitted a letter of resignation to our Board of Directors and thereby resigned as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer of Nutra Pharma Corp., effective immediately.

Appointed

Michael Flax

Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer

NUTRA PHARMA CORP

Effective: 2024-03-20
Filed: March 22, 2024, 7:59 PM ET

On March 20, 2024, our Board of Directors unanimously approved of the appointment of Michael Flax, DDS as our Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rik J. Deitsch resigned as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer at NUTRA PHARMA CORP.

Action: resigned
Role: Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer

Exact text from the filing

On March 19, 2024, Mr. Deitsch submitted a letter of resignation to our Board of Directors and thereby resigned as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer of Nutra Pharma Corp., effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Flax was appointed as Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer at NUTRA PHARMA CORP.

Action: appointed
Role: Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer

Exact text from the filing

On March 20, 2024, our Board of Directors unanimously approved of the appointment of Michael Flax, DDS as our Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-24-010998

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.